AGS 8M4Alternative Names: AGS-8M4; ASP 6183
Latest Information Update: 12 Nov 2016
At a glance
- Originator Agensys
- Class Antineoplastics; Monoclonal antibodies
- Mechanism of Action Surface antigen inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Suspended Ovarian cancer
Most Recent Events
- 30 Aug 2010 Astellas Pharma and Agensys terminate a phase I trial [NCT01016054] in Ovarian cancer in USA
- 02 Feb 2010 Phase-II clinical trials in Ovarian cancer in USA (IV)